Scheduled and Breakthrough Opioid Use for Cancer Pain in an Inpatient Setting at a Tertiary Cancer Hospital
Conclusions: BTO/SCH ratios are frequently prescribed higher than the recommended dose. Daily pain scores, BTO MEDDs, scheduled opioid MEDDs, and total MEDDs were higher among the SCC group than the pre-SCC group, but the number of BTO doses/day was lower.PMID:38534934 | PMC:PMC10969060 | DOI:10.3390/curroncol31030101 (Source: Current Oncology)
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Aline Rozman de Moraes Elif Erdogan Ahsan Azhar Suresh K Reddy Zhanni Lu Joshua A Geller David Mill Graves Michal J Kubiak Janet L Williams Jimin Wu Eduardo Bruera Sriram Yennurajalingam Source Type: research
Ovarian Cancer in the Older Manitoban Population-Treatment Tolerance and Cancer-Related Outcomes: A Manitoba Ovarian Cancer Outcomes (MOCO) Group Study
CONCLUSIONS: Our study demonstrated a high rate of chemotherapy dose reduction and discontinuation in the elderly epithelial ovarian cancer population. Further research is needed to identify risk factors for treatment discontinuation and intolerance in this population.PMID:38534935 | PMC:PMC10969362 | DOI:10.3390/curroncol31030102 (Source: Current Oncology)
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Lesley F Roberts Pascal Lambert Mark W Nachtigal Alon D Altman Erin Dean Source Type: research
Barriers and Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays across Canada
The objective was to identify challenges and opportunities for change in terms of equitable and timely access to biomarker testing and reporting at the education, delivery, laboratory, patient, and health-system levels in Canada. Challenges identified included: limited patient and clinician awareness of genomic medicine options with need for formal education strategies; failure by clinicians to discuss genomic medicine with patients; delays in or no access to hereditary testing; lack of timely reporting of results; intra- and inter-provincial disparities in access; lack of funding for patients to access testing and for lab...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Stephanie Snow Christine Brezden-Masley Michael D Carter Neesha Dhani Cassandra Macaulay Ravi Ramjeesingh Michael J Raphael Monika Slovinec D'Angelo Filomena Servidio-Italiano Source Type: research
The REthinking Clinical Trials Program Retreat 2023: Creating Partnerships to Optimize Quality Cancer Care
Curr Oncol. 2024 Mar 6;31(3):1376-1388. doi: 10.3390/curroncol31030104.ABSTRACTPatients, families, healthcare providers and funders face multiple comparable treatment options without knowing which provides the best quality of care. As a step towards improving this, the REthinking Clinical Trials (REaCT) pragmatic trials program started in 2014 to break down many of the traditional barriers to performing clinical trials. However, until other innovative methodologies become widely used, the impact of this program will remain limited. These innovations include the incorporation of near equivalence analyses and the incorporati...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Ana-Alicia Beltran-Bless Mark Clemons Lisa Vandermeer Khaled El Emam Terry L Ng Sharon McGee Arif Ali Awan Gregory Pond Julie Renaud Gwen Barton Brian Hutton Marie-France Savard Source Type: research
Outpatient Embedded Palliative Care for Patients with Advanced Thoracic Malignancy: A Retrospective Cohort Study
Curr Oncol. 2024 Mar 7;31(3):1389-1399. doi: 10.3390/curroncol31030105.ABSTRACTAlthough cancer care is often contextualized in terms of survival, there are other important cancer care outcomes, such as quality of life and cost of care. The ASCO Value Framework assesses the value of cancer therapies not only in terms of survival but also with consideration of quality of life and financial cost. Early palliative care for patients with advanced cancer is associated with improved quality of life, mood, symptoms, and overall survival for patients, as well as cost savings. While palliative care has been shown to have numerous be...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Mary C Boulanger Margaret D Krasne Ethan K Gough Samantha Myers Ilene S Browner Josephine L Feliciano Source Type: research
< sup > 177 < /sup > Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice
This article aims to review the evidence from prospective phase 2 and 3 clinical trials and meta-analyses of observational studies on the use of 177Lu-PSMA-617 in prostate cancer and discuss how Canadian clinicians might best apply these data in practice. The selection of appropriate patients, the practicalities of treatment administration, including necessary facilities for treatment procedures, the assessment of treatment response, and the management of adverse events are considered. Survival benefits were observed in clinical trials of 177Lu-PSMA-617 in patients with progressive, PSMA-positive mCRPC who were pretreated ...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Kim N Chi Steven M Yip Glenn Bauman Stephan Probst Urban Emmenegger Christian K Kollmannsberger Patrick Martineau Tamim Niazi Fr édéric Pouliot Ricardo Rendon Sebastien J Hotte David T Laidley Fred Saad Source Type: research
The Development and Testing of a Patient Decision Aid for Individuals with Homologous Recombinant Proficient Ovarian Cancer Who Are Considering Niraparib Maintenance Therapy
Curr Oncol. 2024 Mar 8;31(3):1416-1425. doi: 10.3390/curroncol31030107.ABSTRACTNew treatments for ovarian cancer are available that require trade-offs between progression-free survival and quality of life. The aim of this study was to develop a decision aid for patients with homologous recombinant proficient (HRP) tumors, as the benefit-harm ratio of niraparib needs consideration. This decision aid was created with a systematic and iterative development process based on the Ottawa Decision Support Framework. The decision aid was user-tested for acceptability, usability, and comprehensibility using a survey completed by a s...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Laura Hopkins Mark Carey Linda Brown Sabryna McCrea Mark Milne Dawne Tokaryk Dawn Stacey Source Type: research
Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development
Curr Oncol. 2024 Mar 8;31(3):1426-1444. doi: 10.3390/curroncol31030108.ABSTRACTThis is a consensus-based Canadian guideline whose primary purpose is to standardize and facilitate the management of chronic graft-versus-host disease (cGvHD) across the country. Creating uniform healthcare guidance in Canada is a challenge for a number of reasons including the differences in healthcare authority structure, funding and access to healthcare resources between provinces and territories, as well as the geographic size. These differences can lead to variable and unequal access to effective therapies for GvHD. This document will prov...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Dennis Dong Hwan Kim Gizelle Popradi Kylie Lepic Kristjan Paulson David Allan Ram Vasudevan Nampoothiri Sylvie Lachance Uday Deotare Jennifer White Mohamed Elemary Kareem Jamani Christina Fraga Christopher Lemieux Igor Novitzky-Basso Arjun Datt Law Rajat Source Type: research
Peritoneal Metastatic Gastric Cancer: Local Treatment Options and Recommendations
Curr Oncol. 2024 Mar 9;31(3):1445-1459. doi: 10.3390/curroncol31030109.ABSTRACTPeritoneal metastasis is a common finding in patients with advanced gastric cancer. Beyond systemic chemotherapy, additive local treatments such as cytoreductive surgery and intraperitoneal chemotherapy are considered an inherent part of different multimodal treatment concepts for selected patients with peritoneal metastatic gastric cancer. This review article discusses the role of cytoreductive surgery (CRS) and intraperitoneal chemotherapy, including HIPEC, NIPS, and PIPAC, as additive therapeutic options with curative and palliative intent.PM...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Miklos Acs Pompiliu Piso Gabriel Glockzin Source Type: research
Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action
Curr Oncol. 2024 Mar 11;31(3):1460-1469. doi: 10.3390/curroncol31030110.ABSTRACTCanada has one of the most complex and rigorous drug approval and public reimbursement processes and is, unfortunately, one of the countries with the longest delays in drug access. To assess the overall impact of systemic delays in access to cancer therapy, a targeted literature review (TLR) was performed to identify studies associated with the clinical, economic, and quality of life impacts of delayed access to oncology drugs. Using MEDLINE/PubMed databases and snowballing, four unique records met the eligibility criteria. Results revealed tha...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Sandeep Sehdev Joanna Gotfrit Martine Elias Barry D Stein Source Type: research
Overview of the Engagement Process to Develop the Future of Cancer Impact (FOCI) Report in Alberta: The Power of Collective Action
Curr Oncol. 2024 Mar 12;31(3):1470-1476. doi: 10.3390/curroncol31030111.ABSTRACTThis commentary provides a detailed overview of the extensive stakeholder engagement efforts critical to the development of the Future of Cancer Impact (FOCI) in Alberta report. The overarching aim of the FOCI report was to support informed and strategic discussions and actions that will help key stakeholders in the province prepare for a future with increasing cancer incidence and survival. Employing a comprehensive approach and a diverse range of engagement activities, insights from a wide spectrum of stakeholders were gathered and subsequent...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Anna Pujadas Botey Tara R Bond Eliya Farah Chantelle Carbonell Stacey Dyck Angela Estey Douglas A Stewart Darren R Brenner Paula J Robson Source Type: research
Chylous Ascites Associated with Advanced Pancreatic Cancer That Improved with Appropriate Treatment: A Case Report
Curr Oncol. 2024 Mar 12;31(3):1477-1482. doi: 10.3390/curroncol31030112.ABSTRACTChylous ascites is a rare form of ascites with high triglyceride content arising from the thoracoabdominal lymph nodes in the peritoneal cavity due to various benign or malignant etiologies, including pancreatic cancer. During cancer chemotherapy, the accumulation of ascites can lead to the deterioration of the patient's general condition, making chemotherapy administration difficult, and resulting in a poor prognosis. We encountered a rare case of chylous ascites complicated by advanced pancreatic cancer. The patient presented with a discrepan...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Hiroo Imai Ken Saijo Noriko Takenaga Keigo Komine Kota Ouchi Yuki Kasahara Shiori Ishikawa Keiju Sasaki Yuya Yoshida Hidekazu Shirota Masanobu Takahashi Chikashi Ishioka Source Type: research
A Retrospective Age Analysis of the Ambulatory Oncology Patient Satisfaction Survey: Differences in Satisfaction across Dimensions of Person-Centred Care and Unmet Needs among Older Adults Receiving Cancer Treatment
In this study, we explored the age differences in satisfaction across six dimensions of person-centred care and in the proportions of unmet needs across eight types of issues, with specific attention to older adults. Using three age groups (18-39, 40-64, 65+), only the physical comfort dimension showed significantly lower satisfaction among those aged 65+ years. Using five age groups (18-39, 40-64, 65-74, 75-84, 85+), significantly lower levels of satisfaction were found related to 'physical comfort' for those aged 65-74 and 75-84, 'coordination and continuity of care' for those aged 75-84 and 85+, and 'information, commun...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Fay J Strohschein Siwei Qi Sandra Davidson Claire Link Linda Watson Source Type: research
The Influence of Additional Treatments on the Survival of Patients Undergoing Transarterial Radioembolization (TARE)
Curr Oncol. 2024 Mar 13;31(3):1504-1514. doi: 10.3390/curroncol31030114.ABSTRACTThe aim of this study was to present our preliminary experience with transarterial radioembolization (TARE) using Yttrium-90 (90Y), compare the cancer-specific survival (CSS) of patients with hepatocellular carcinoma (HCC) and colorectal cancer (CRC) liver metastases undergoing TARE, and investigate the influence of additional treatments on CSS. Our database was interrogated to retrieve patients who had undergone TARE using Yttrium-90 (90Y) glass or resin microspheres. Kaplan-Meier curves and the log-rank test were employed to conduct survival ...
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Natale Quartuccio Salvatore Ialuna Daniele Scalisi Fabio D'Amato Maria Rosa Barcellona Maria Grazia Bavetta Giorgio Fusco Enrico Bronte Emma Musso Fabrizio Bronte Viviana Picciotto Antonio Carroccio Francesco Verderame Giuseppe Malizia Angelina Cistaro Fa Source Type: research
Biomarker Turnaround Times and Impact on Treatment Decisions in Patients with Advanced Non-Small Cell Lung Carcinoma at a Large Canadian Community Hospital with an Affiliated Regional Cancer Centre
Conclusions: This study emphasizes the need for the expansion of regional resources to meet the clinical needs of advanced NSCLC patients treated at a regional cancer centre which uses an off-site molecular laboratory.PMID:38534948 | PMC:PMC10969576 | DOI:10.3390/curroncol31030115 (Source: Current Oncology)
Source: Current Oncology - March 27, 2024 Category: Cancer & Oncology Authors: Katelyn E Fleming Ava Hupel Hamid Mithoowani Tea Lulic-Kuryllo Mario Valdes Source Type: research
